31Dec
21Dec
Your employer may soon give you a 401(k) match for your student loan payments
In the new year, some employers will begin making matching 401(k) contributions into a retirement account for their employees’ student loan payments, a change that could be “transformational” for borrowers who may have trouble saving for retirement while paying down their debt. Different provisions in the legislation have different implementation dates: 401(k) matches for student loan payments will begin after Jan. 1. That comes just a few months after federal student loan payments resumed after a three and a half...
20Dec
This Startup Can Improve Cancer Screenings, Starting With Mammograms
As of March 2023, the Food and Drug Administration required that mammogram facilities start notifying patients about their breast density so that they know their risks and can act accordingly, such as pursuing another imaging option. As Marissa Fayer MBA, CEO of Deeplook Medical, adds, a post-mammogram note about breast density puts the onus around patients to decide their next steps and balance risks and costs. Deeplook Medical, in contrast, can give information beyond just breast density to help empower...
19Dec
Eco Soul Home to double its presence in international markets
Eco-friendly products brand Eco Soul Home is planning to expand its presence to nine more countries by 2024 end. At present, the brand is present in 11 countries by 2024 end. At present, the brand is present in 11 countries across the world, Rahul Singh, co-founder, Eco Soul Home told ETRetail. Along with offering its products at all major e-commerce platforms, the products of the brand are also available at 18,000 retail stores worldwide. ""We started our journey in 2020...
16Dec
In a World First, a Patient’s Antibody Cells Were Just Genetically Engineered
Our B cells help prevent us from getting sick. Their job is to make antibodies, immune system proteins that fight off viruses and other foreign invaders. And they make a lot of antibodies—thousands of them every second. What if these antibody factories could be harnessed to make other things the body needs? That’s the idea behind a trial launched by Seattle-based biotech company Immusoft. The company announced today that its scientists have genetically programmed a patient’s B cells and put...
16Dec
Researchers Genetically Program B Cells to Treat Genetic Disorder
A Seattle-based biotech company is conducting a trial using genetically programmed B cells to treat a genetic disorder called mucopolysaccharidosis type I (MPS I). The disorder causes a lack of an essential enzyme that breaks down long-chain sugars in the body. This enzyme deficiency leads to life-threatening symptoms, including cloudy eyes, respiratory problems, cognitive issues, and enlarged organs. Patients with MPS I currently receive weekly infusions of the missing enzyme, but Immusoft, the biotech company conducting the trial, aims to...
16Dec
15 Gifts You Want This Year Because You’re An Adult & Socks Are Awesome
Archer Roose Bubbly Rose 12-Can Pack - Cracking a bottle of bubbly might seem indulgent when you’re the only one who wants a glass, but thanks to indie brand Archer Roose, you can have one anytime you like. This wine-in-a-can maker also offers different wines, sparkling and otherwise, and you can even mix and match your selections in an Explorer Pack. Read more >>
16Dec
Immusoft Administers the First Engineered B Cell in a Human Clinical Trial
Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced the first patient dosed with engineered B cell therapy ISP-001 in a Phase 1 trial in MPS I, at M Health Fairview University of Minnesota Medical Center. MPS I is a rare, genetic disease that affects the body’s ability to produce the enzyme alpha-L-iduronidase (IDUA), which is an essential enzyme that helps...
15Dec
Quthero Accepted into Prestigious MaRS-adMare Tx Accelerator
Quthero, a biotech company with a unique, patented Q-peptide platform technology was accepted into the MaRS – adMare Therapeutics (Tx) Accelerator which provides a distinctive ecosystem for the development of novel therapeutics in Ontario and Canada. Quthero's technology enables and accelerates full regeneration of a patient's natural tissue with minimal scarring. ""The partnership between MaRS and adMare presents Quthero with a unique opportunity to access the most experienced players in the development of new therapeutics. We are excited...
13Dec